ILLUMA Luna PN Booster 2.5ml x 2 Syringe

iLLUMA

Injectable Skin Boosters

Under-eye polynucleotide (PN) injectable skin booster

Description

ILLUMA Luna PN Booster 2.5ml x 2 Syringe is a next-generation polynucleotide (PN) skin booster specifically engineered for the delicate under-eye and periocular area. Its innovative formula combines non-crosslinked hyaluronic acid with a high concentration of polynucleotides and a targeted peptide complex to enhance cell permeability and promote a gradual, slow release of HA gel. This mechanism extends the active time of PN in the tissue and prolongs the overall rejuvenating effect. Each syringe delivers a powerful dual action of regeneration and brightening by stimulating dermal repair, improving under-eye wrinkles, increasing moisture and targeting dark circles and pigmentation. ILLUMA Luna stands out for containing significantly more PN (around 10 mg polynucleotide per standard syringe) than many comparable products, together with 5 mg hyaluronic acid and pharmaceutical-grade peptides, making it suitable for the sensitive skin around the eyes. The 2.5 ml x 2 pack offers ample product for full tear-trough and periocular treatment protocols by trained professionals.

Bnefits

Specially designed for the delicate under-eye and periocular area, addressing fine lines, dark circles and dullness.
Combines polynucleotides with non-crosslinked hyaluronic acid to enhance cellular regeneration and deep hydration.
Slow, gradual release of HA gel increases cell permeability and prolongs the active time and efficacy of PN in the skin.
High PN content (around 10 mg polynucleotide per syringe) provides a stronger regenerative effect than many standard under-eye boosters.
Improves under-eye wrinkles and fine lines by stimulating collagen and elastin production and enhancing dermal structure.
Brightens and lightens dark circles while improving overall pigmentation around the eyes for a more radiant look.
Increases moisture levels and skin elasticity, leaving the under-eye area plumper, smoother and more youthful.
Uses pharmaceutical-grade raw materials for enhanced safety and tolerability on sensitive under-eye skin.

Indications

Biorevitalisation and rejuvenation of the under-eye and surrounding periocular area.
Reduction of under-eye wrinkles, fine lines and early signs of skin laxity.
Brightening of dark circles and improvement of uneven pigmentation under the eyes.
Improvement of skin hydration, texture and elasticity in the under-eye region.
Regenerative support for tired, photo-aged or dull skin around the eyes.
Professional aesthetic treatment in suitable adult patients seeking under-eye rejuvenation.

Composition

Non-crosslinked hyaluronic acid (HA): 5 mg per standard syringe (moisturising and plumping agent).
Polynucleotide (PN): 10 mg per standard syringe (DNA-derived regenerative biopolymer supporting tissue repair and cellular regeneration).
Pentapeptide-13: 0.05 mg (peptide to support dermal regeneration and firmness).
Tripeptide-29: 0.05 mg (collagen-supporting peptide that helps improve skin structure).
Dipeptide-2: 0.05 mg (peptide often used to help target puffiness and dark circles).
Pharmaceutical-grade excipients and buffer components suitable for injectable PN/HA formulations (full list supplied in the official product leaflet).

Formulation

Injectable, non-crosslinked hyaluronic acid–based polynucleotide skin booster.
Active components: PN (10 mg), HA (5 mg) plus Pentapeptide-13, Tripeptide-29 and Dipeptide-2 in each standard syringe.
Designed as a PN filler/booster with dual action: regeneration (PN and peptides) and brightening/whitening of under-eye area.
Sterile solution intended for intradermal/mesotherapy-style injection by trained professionals.
Pharmaceutical-grade raw materials formulated specifically for the sensitive under-eye skin.

Packaging

Box containing 2 syringes, each with 2.5 ml of ILLUMA Luna PN Booster (total volume 5 ml).
Each syringe is prefilled, sterile and individually packaged, labelled with product name, volume (2.5 ml), batch number and expiry date.
Outer carton branded as ILLUMA Luna PN Booster, indicating its role as an under-eye polynucleotide skin booster.
Supplied for professional use via aesthetic wholesalers such as The Crystal Pharmacy and others.

Usage

For professional use only; treatment must be performed by a qualified medical or aesthetic practitioner trained in injectable under-eye procedures.
Assess the patient’s medical history, skin condition, expectations and contraindications; obtain informed consent and follow clinic protocols.
Cleanse and disinfect the under-eye and periocular area thoroughly using appropriate antiseptic measures and maintain aseptic technique throughout.
Inject small aliquots of ILLUMA Luna intradermally or in the superficial subdermal plane in the under-eye area, using micro-depot, linear or mesotherapy-style techniques according to official protocol and practitioner preference.
Distribute the product evenly along the tear trough and surrounding area, taking care to avoid intravascular injection and to minimise trauma.
Recommended treatment course (from manufacturer and clinic protocols): perform 3–4 treatment sessions at approximately 4-week intervals to achieve optimal regeneration and brightening.
Evaluate results periodically and consider additional maintenance sessions based on clinical response and patient goals.
After treatment, advise the patient to avoid makeup application directly on the treated area for the rest of the day, avoid strenuous exercise, saunas, swimming and excessive sun exposure for at least 24–48 hours, and to use high-factor SPF around the eyes as appropriate.
Dispose of used syringes and needles immediately in approved sharps containers and handle all materials according to local clinical waste regulations.

Contraindications

Known hypersensitivity or allergy to hyaluronic acid, polynucleotides, peptides or any other component of the formulation.
Active skin infections, inflammation, dermatitis or lesions in the intended treatment area.
History of severe keloid or hypertrophic scarring in the periocular region.
Significant systemic illness, uncontrolled autoimmune disease or coagulation disorders, unless carefully evaluated and approved by a medical practitioner.
Pregnancy and breastfeeding, as a precaution due to limited safety data in these populations.
Use in patients under 18 years of age unless allowed by local regulations and clinical judgement.
Any additional contraindications or precautions specified in the official ILLUMA Luna product information or by local clinical guidelines for under-eye injectables.

Adverse Effects

Common, usually transient injection-site reactions such as redness, swelling, mild pain, tenderness, bruising or small papules at the injection points.
Temporary under-eye puffiness or oedema, typically resolving within a few days post-procedure.
Rare local infection, abscess formation or prolonged inflammation if aseptic technique is inadequate.
Possible allergic or hypersensitivity reactions to active ingredients or excipients, presenting as persistent redness, itching or swelling.
Very rare but serious risk of vascular compromise or embolic events associated with injectable periocular treatments; requires immediate recognition and management according to emergency protocols.
Potential post-inflammatory hyperpigmentation or transient changes in pigmentation, particularly in darker skin types or in patients prone to PIH.

Storage Conditions

Store in a cool, dry place within the temperature range specified in the product leaflet (typically controlled room temperature; avoid extremes).
Keep in original packaging to protect syringes from light and contamination until use.
Do not freeze; avoid exposure to excessive heat, direct sunlight or sudden temperature fluctuations.
Do not use if the packaging is damaged, if the solution appears cloudy or contains particles, or if the expiry date has passed.
Once a syringe has been used, discard any remaining product; do not reuse or attempt to re-sterilise.

Duration

Typical protocol involves 3\u20134 sessions spaced about 4 weeks apart for initial correction, followed by maintenance treatments as needed based on patient response and practitioner recommendation.

Onset

Initial improvements in hydration and brightness may be noticeable within days after treatment, with progressive reduction in fine lines, dark circles and texture irregularities becoming more evident over several weeks and after completion of the 3\u20134 session course.